报告题目：Tumour heterogeneity, cellular plasticity and single cell sequencing
报告人：Xin Lu, Ph.D.
Professor and Director, Ludwig Institute for Cancer Research
Oxford University, UK
Elected Member, European Molecular Biology Organization
Elected Fellow, the Academy of Medical Sciences
Professor Lu’s group has long standing research interests in tumour suppression. She was one of the first researchers to show that the tumour suppressor p53 responds to both oncogene activation and DNA damaging signals. Her group was one of the first to demonstrate how to selectively activate p53 to kill cancer cells, through identification and characterization of the evolutionarily conserved ASPP family of proteins.
Tumour heterogeneity underlies differences in cancer progression and responses to therapy and is caused by genetic and cellular heterogeneity. Cellular heterogeneity is itself caused by cellular plasticity. Over 80% of human tumours originate from epithelial cells and these cells have the unique property of cell polarity, which acts as a first line of defence against infection and a barrier against cancer cell invasion. In this session we will discuss how epithelial cell plasticity is controlled by molecular switches operating at levels from cell polarity and cell adhesion that senses external signals such as infection to gene regulation by transcription factors and cell fate determination. We will also illustrate how single cell sequencing technology can enable us to study cellular heterogeneity in vivo in human tissues.